RxDoctor Payments Data

Kelly Kelley

Family · Columbia, TNNPI 1972882504

Payments from drug & device makers

$5,777in general payments, 2019–2025

Across 296 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$751
  • Novo Nordisk$514
  • AbbVie$501
  • Amgen$380
  • Bayer$348
  • GSK$296
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$5,70499%
  • Education$731%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,777 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$56,492
Medicare patients
231
Services billed
1,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$51,178
TrulicityDulaglutide23$45,711
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$45,251
EliquisApixaban35$43,788
FarxigaDapagliflozin Propanediol39$41,036
OzempicSemaglutide27$38,923
XareltoRivaroxaban24$28,777
JanuviaSitagliptin Phosphate13$19,429
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,294
RybelsusSemaglutide12$16,522
TradjentaLinagliptin17$13,055
Repatha SureclickEvolocumab13$6,849
Spiriva RespimatTiotropium Bromide12$5,952
Atorvastatin Calcium238$2,393
Rosuvastatin Calcium128$1,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$202$70,18566 claims
AstraZenecaFarxiga, Breztri Aerosphere$751$58,33064 claims
Novo NordiskOzempic, Rybelsus$514$55,44539 claims
Lilly USA, LLCTrulicity$271$45,71123 claims
GSKTrelegy Ellipta$296$45,25156 claims
PfizerEliquis$195$43,78835 claims
Johnson & JohnsonXarelto$140$28,77724 claims
MerckJanuvia$71$19,42913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Columbia

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →